What is Pherecydes Pharma?
Pherecydes Pharma is a biotechnology company focused on developing innovative therapeutic solutions. While the provided description appears to be for a lottery results website and is likely a data error, Pherecydes Pharma's funding history suggests a focus on advanced research and development within the life sciences sector. The company's consistent access to capital, including Series B financing, indicates strong investor confidence in its scientific endeavors and its potential to disrupt the pharmaceutical market.
How much funding has Pherecydes Pharma raised?
Pherecydes Pharma has raised a total of $15.5M across 3 funding rounds:
Series A
$2.3M
Unspecified
$2.9M
Series B
$10.3M
Series A (2014): $2.3M with participation from Auriga Partners
Unspecified (2015): $2.9M, investors not publicly disclosed
Series B (2018): $10.3M supported by Fa-Dièse, Go Capital, Auriga Partners, and Omnes Capital
Key Investors in Pherecydes Pharma
Fa-Dièse
Fa-Dièse is a Paris-based micro VC fund specializing in early-stage startups with high growth potential, investing in digital, hardware, and life sciences fields.
Go Capital
GEOC, a China-Israel fund, invests in Israeli High-tech companies in Life Sciences, Digital/3D printing, Cyber Security, Artificial Intelligence, and IOT, with a focus on assisting companies in penetrating the Chinese market.
Auriga Partners
Auriga Partners is an investment firm that has backed Pherecydes Pharma in its growth stages.
What's next for Pherecydes Pharma?
With a significant capital infusion from its latest strategic investment, Pherecydes Pharma is poised for accelerated development and market penetration. The company's enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially preparing for later-stage commercialization. Future strategic moves will likely involve leveraging this backing to solidify its position in the competitive biotech landscape and bring its novel therapies to patients.
See full Pherecydes Pharma company page
